Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients

Table 2 Comparison of the main characteristics of HIV infected-men enrolled in the study according to their CD4⁺ cells count at the time of cART initiation

	Blood CD4⁺ T count at the time of diagnosis (cells/mm³)		p value
	>350 “high-level CD4 group” (n = 9)	<350 “low-level CD4 group” (n = 15)	p value
At the time of diagnosis
Route of contamination (%)
MSM or bisexual	100	86.7	0.51
Heterosexual	0	13.3	0.51
Stage CDC of HIV infection (%)
A (PHI)	62.5	6.7	0.01
B or C	0	40	0.05
At the time of blood and biopsy sampling
Age, median in years [range]	48 [28.5–49.5]	53 [46–61]	0.03
Time since diagnosis of HIV infection, median in months [range]	40 [27.5–105.5]	44 [26–48]	0.63
Total time on cART, median in months [range]	34 [18.5–60]	42 [24–46]	0.68
cART regimen (%)
3 NRTI	100	93.3	0.009
2 NRTI/1 NNRTI	55.5	53.3	1
2 NRTI/1 PI	44.4	46.6	1
2 NRTI/1 II	0	13.3	0.51
At the time of cART initiation
Time since diagnosis of HIV infection, median in months [range]	2 [0.5–73.5]	0 [0–1]	0.05
Initiation at PHI stage (%)	33.3	6.7	0.13
CD4⁺ T cells/mm³, median [range]	450 [427–695]	98 [31–257]	<0.0001
PVL in log₁₀ copies/ml, median [range]	4.97 [4.24–6.1]	5.52 [5.17–5.94]	0.25

cART combined antiretroviral therapy, CDC centers for disease control and prevention, II integrase inhibitors, PHI primary HIV infection, PVL plasmatic viral load, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitors, PI protease inhibitors

ISSN: 1742-4690